产品展示
优质供应
详细内容
SNU-182（人肝癌细胞）
上海义森生物科技有限公司
ATCC® Number: CRL-2235™ Designations: SNU-182 Depositors: J Park Biosafety Level: 2 [CELLS CONTAIN HEPATITIS B VIRUS ] Shipped: frozen
SNU-182（人肝癌细胞）
上海义森生物科技有限公司
ATCC® Number: CRL-2235™ Designations: SNU-182 Depositors: J Park Biosafety Level: 2 [CELLS CONTAIN HEPATITIS B VIRUS ] Shipped: frozen
SNU-182（人肝癌细胞）
上海义森生物科技有限公司
| ATCC® Number: | CRL-2235™ |
| Designations: | SNU-182 |
| Depositors: | J Park |
| Biosafety Level: | 2 [CELLS CONTAIN HEPATITIS B VIRUS ] |
| Shipped: | frozen |
SNU-182（人肝癌细胞）
上海义森生物科技有限公司
| Medium & Serum: | See Propagation |
| Growth Properties: | adherent |
| Organism: | Homo sapiens （human） |
| Morphology: | epithelial |
| Source: | Organ: liver Tumor Stage: grade III/IV Disease: hepatocellular carcinoma |
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| Restrictions: | This line is available under the following restrictions: 1.） The cell line was deposited for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2.） Any proposed commercial use of these cells or products produced by them must first be negotiated with Jae-GaHB-Park, Director, Korean Cell Line Bank, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea. Telephone （02） 760-3380, Fax （02） 742-4727. 3.） In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publication （Int. J. Cancer 62:276-282, 1995）. |
上海义森生物科技有限公司
